Bridgeway Capital Management’s IGC Pharma IGC Stock Holding History

Bridgeway Capital Management’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-69,000	Closed	-$19.3K	–	1339
2023 Q4	$19.3K	Hold	69,000	–	–	﹤0.01%	1341
2023 Q3	$24.8K	Hold	69,000	–	–	﹤0.01%	1338
2023 Q2	$21.5K	Hold	69,000	–	–	﹤0.01%	1360
2023 Q1	$23.4K	Hold	69,000	–	–	﹤0.01%	1350
2022 Q4	$21.9K	Hold	69,000	–	–	﹤0.01%	1336
2022 Q3	$30K	Sell	69,000 -70,000	-50%	-$37.3K	﹤0.01%	1373
2022 Q2	$74K	Hold	139,000	–	–	﹤0.01%	1254
2022 Q1	$132K	Hold	139,000	–	–	﹤0.01%	1235
2021 Q4	$136K	Hold	139,000	–	–	﹤0.01%	1196
2021 Q3	$206K	Sell	139,000 -70,000	-33%	-$113K	﹤0.01%	1200
2021 Q2	$343K	Sell	209,000 -39,700	-16%	-$60.6K	0.01%	1178
2021 Q1	$445K	Buy	248,700 +56,500	+29%	+$103K	0.01%	1119
2020 Q4	$300K	Hold	192,200	–	–	0.01%	1118
2020 Q3	$200K	Buy	192,200 +65,000	+51%	+$66.1K	﹤0.01%	1176
2020 Q2	$76K	Buy	+127,200	New	+$69K	﹤0.01%	1259

Other funds holding IGC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Bridgeway Capital Management's IGC Position: Q1 2024 in Review

Bridgeway Capital Management sold out of IGC Pharma (IGC) in Q1 2024, closing a stake of 69,000 shares — an estimated $19.3K sold.

Bridgeway Capital Management first reported a position in IGC in Q2 2020 and held it in 15 quarters. The position peaked at $445K in Q1 2021. 25 funds tracked by Wall St. Rank hold IGC as of Q1 2024.

Bridgeway Capital Management reported no remaining IGC Pharma position as of Q1 2024 after selling out during the quarter.
Bridgeway Capital Management sold 69,000 IGC Pharma shares in Q1 2024, an estimated $19.3K.
Bridgeway Capital Management first reported a position in IGC Pharma in Q2 2020 and held it in 15 quarters.
Bridgeway Capital Management's IGC Pharma position peaked at $445K in Q1 2021.
25 funds tracked by Wall St. Rank held IGC Pharma as of Q1 2024.

Based on Bridgeway Capital Management's 13F filing for Q1 2024, filed 15 May 2024.